Anocca AB, a T cell receptor-engineered T cell (TCR-T) cellular therapeutics company, and EmendoBio Inc., a nuclease discovery and gene editing therapeutics company, have entered a non-exclusive licensing agreement for the use of EmendoBio’s novel OMNI-A4 nuclease to accelerate the manufacture and development of Anocca’s pipeline of TCR-T cell therapies for difficult-to-treat solid cancers.
 
“Integrating EmendoBio’s nuclease into our manufacturing process supports Anocca’s aim of generating the highest-quality cell therapy products. This next-generation gene editing system provides the precision and efficiency needed to scale out production of our growing libraries of TCR-T products in a high-precision manufacturing process. We are excited to work with EmendoBio to develop gene-edited TCR-T cell therapies as we prepare for our first clinical program targeting the KRAS driver mutation in a hard-to-treat solid cancer” said Anocca’s CEO and co-founder, Reagan Jarvis.
 
“This non-exclusive licensing agreement marks a significant milestone in the field of T cell therapy,” said Dr. Ei Yamada, Director of EmendoBio. “Together with Anocca, we are embracing the shared vision of harnessing the potential of gene editing and cellular therapies to make a profound impact on patient outcomes. Our combined expertise will unlock novel avenues for therapeutic development and push the boundaries of what’s possible in advanced medicine.”
 
Anocca recently received certification of GMP compliance and a manufacturing license from the Swedish regulators for its cell therapy production facility. EmendoBio’s technology strengthens Anocca’s manufacturing capability and provides a foundation for the goal of reaching more patients faster with personalized treatments targeting the underlying genetic drivers of hard-to-treat cancers. The licensed gene editing technology is part of EmendoBio’s portfolio of proprietary nucleases developed to be highly active and specific for cell therapy applications.